COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study
AbstractObjective Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disease characterized by chronic complement-mediated hemolysis. The concentrated outbreak of coronavirus disease 2019 (COVID-19) in China after 6 December 2022, provided an opportunity to observe the disease course of PNH...
Main Authors: | Leyu Wang, Qinglin Hu, Yuan Yang, Miao Chen, Chen Yang, Bing Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Annals of Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2023.2274510 |
Similar Items
-
Severe hemolytic exacerbations of Chinese PNH patients infected SARS‐CoV‐2 Omicron
by: Hui Yang, et al.
Published: (2023-08-01) -
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
by: Michela Sica, et al.
Published: (2017-06-01) -
Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan
by: Bruno Fattizzo, et al.
Published: (2022-12-01) -
COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
by: Sufana Shikdar, et al.
Published: (2021-10-01) -
The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial
by: Aleksandr D. Kulagin, et al.
Published: (2021-11-01)